Postmarketing Analysis of Aflibercept-Related Sterile Intraocular Inflammation

Authors:

Abstract
The American Society of Retina Specialists (ASRS) Therapeutic Surveillance Subcommittee (TSC) serves as an independent task force to objectively monitor drug- and device-related adverse events on behalf of the greater community of retina specialists and their patients. The ASRS TSC has maintained a history of prompt investigation of adverse events, including identification of a fungal endophthalmitis outbreak related to improperly compounded Brilliant Blue G in a single responsible pharmacy,1 which was subsequently closed, and comprehensive classification and analysis of postmarketing adverse events reported after ocriplasmin (Jetrea; ThromboGenics Inc) administration. Within the first 3 months of aflibercept use (Eylea; Regeneron Pharmaceuticals Inc) after approval by the Food and Drug Administration (FDA) in November 2011, a cluster of aflibercept-related sterile intraocular inflammation was similarly reported. The ASRS TSC received reports of 15 cases in those 3 months, surveyed the reporting physicians for detailed information surrounding these events, and reported findings of sterile inflammation not associated with any identifiable causative factors.2 Of note, 47% of those cases were successfully treated with a return to baseline vision with topical corticosteroids alone, demonstrating that invasive interventions, including vitreous biopsy and intravitreal antibiotic administration or vitrectomy, may be avoided in select circumstances. Subsequent cases of sterile inflammation after aflibercept have continued to be submitted to the TSC. This report serves to describe these events and to analyze these data for any associated factors, consistent with the mission of the TSC to investigate and inform the ophthalmology community regarding drug- and device-related safety events.

This publication has 2 references indexed in Scilit: